FDA Approves Revolutionary 12-Month Flea and Tick Treatment for Dogs

The U.S. Food and Drug Administration has approved a groundbreaking veterinary treatment that promises to transform how dog owners protect their pets from fleas and ticks. Bravecto Quantum, the first injectable flea and tick preventative offering up to 12 months of protection with a single dose, received FDA approval this week.

A Game-Changing Approach to Parasite Prevention

This innovative treatment represents a significant advancement in veterinary medicine. Unlike traditional preventatives that require monthly or quarterly administration, Bravecto Quantum provides extended protection through a single veterinarian-administered injection.

The treatment is approved for dogs and puppies aged 6 months and older, offering pet owners a convenient alternative to frequent dosing schedules. This extended protection period could be particularly beneficial for pet owners who struggle with regular medication schedules or live in areas requiring year-round parasite protection.

Expert Insights on the New Treatment

Dr. Tina Wismer, senior director of toxicology at ASPCA Poison Control, highlighted the treatment’s potential benefits. “Fluralaner, the active ingredient in Bravecto Quantum, can be an important part of parasite control depending on where pet owners live in the country,” she explained. “A long-term flea and tick preventative can be a useful option for dog owners who live in areas where year-round protection is necessary, or for those who might not be able or remember to administer treatment on a monthly or quarterly basis.”

Professional Administration Required

The injectable treatment must be administered by a licensed veterinarian, who will determine the appropriate protection period—either 8 or 12 months—based on local tick species and environmental factors. This professional oversight ensures proper dosing and allows for monitoring of potential side effects.

Safety Considerations

While Bravecto Quantum belongs to the isoxazoline class of medications, which are commonly used and generally safe, pet owners should be aware of potential neurological side effects. Some dogs may experience muscle tremors or seizures, making veterinary consultation essential, particularly for dogs with a history of neurological issues.

Julie Cappiello from Voters For Animal Rights acknowledged the treatment’s convenience while emphasizing the importance of careful consideration. “As someone who spends a great deal of time outdoors with my dog, I see the convenience of a long-lasting, 12-month flea and tick preventative like Bravecto Quantum,” she said. “However, it’s important to recognize that no single treatment is right for every dog, and all medications come with potential risks.”

Next Steps for Pet Owners

Pet owners interested in this new treatment option should consult their veterinarians to determine if Bravecto Quantum is appropriate for their dogs. This is especially important for pets with pre-existing health conditions or those who have experienced adverse reactions to medications in the past.

The treatment, manufactured by Intervet, Inc. of Rahway, New Jersey, represents a significant step forward in companion animal healthcare, offering both convenience and comprehensive protection against these common parasites.

This FDA approval marks an important milestone in veterinary medicine, providing dog owners with a new tool in the ongoing battle against fleas and ticks while emphasizing the continued importance of professional veterinary care in pet health decisions.